FDA expands approval of Spiriva Respimat inhalation spray for pediatric asthma
Boehringer Ingelheim Pharmaceuticals has announced that the FDA approved SPIRIVA RESPIMAT for the long-term, once-daily maintenance treatment of asthma in people age 6 and older. SPIRIVA RESPIMAT is not a treatment for sudden asthma symptoms.
The FDA approved the Supplemental New Drug Application (sNDA) under a priority review designation, and the FDA also granted pediatric exclusivity to SPIRIVA RESPIMAT in light of the clinical trials conducted by Boehringer Ingelheim.
SPIRIVA RESPIMAT is steroid-free and works differently from other treatment options to open airways to help people breathe better. In its comprehensive clinical trial program, SPIRIVA RESPIMAT demonstrated proven efficacy and safety for patients age 6 and older.
“It is important for healthcare providers to identify and treat patients who may be taking a controller medicine, but who continue to experience uncontrolled asthma symptoms that can make it difficult to breathe and may even cause an exacerbation,” said Bradley E. Chipps, M.D., Capital Allergy & Respiratory Disease Center, Sacramento, California. “As healthcare providers, we need options, like SPIRIVA RESPIMAT, to consider as an add-on treatment to improve asthma symptoms for the broad age range of patients who may need more control.”
SPIRIVA RESPIMAT, which is delivered as two puffs once a day of 1.25mcg per puff, is part of a class of medicines called long-acting muscarinic antagonist (LAMA) and is the only one of its kind approved for asthma. SPIRIVA RESPIMAT was approved in September 2015 for the long-term, once-daily, prescription maintenance treatment of asthma in people age 12 and older. In the treatment of asthma, the maximum benefits in breathing may take up to four to eight weeks.
Asthma is a chronic respiratory disease that can cause airways to become narrower and irritated, making it difficult to breathe. It currently affects nearly 6.3 million American children. Asthma symptoms can be serious, and uncontrolled asthma could lead to emergency room visits, hospital stays and missed days of school.
“This FDA approval expands the indication of SPIRIVA RESPIMAT to a broad range of people, including children, adolescents and adults who may be experiencing uncontrolled asthma,” said Sabine Luik M.D., senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals. “For nearly a century, Boehringer Ingelheim has been focused on addressing serious unmet needs. This approval is further evidence of our ongoing commitment to improving the lives of the patients we serve.”
This FDA approval is based on efficacy and safety data from the phase II and phase III UniTinA-asthma clinical development program, which included more than 150 sites globally with over 6,000 patients, including 804 children (aged 6-11 years).
Upcoming Events
-
21Oct